Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate ezetimibe tablets are an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total c ldl c apo b and non hdl c in patients with primary hyperlipidemia alone or in combination with an hmg coa reductase inhibitor statin 1 1 reduce elevated total c ldl c apo b and non hdl c in patients with mixed hyperlipidemia in combination with fenofibrate 1 1 reduce elevated total c and ldl c in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin 1 2 reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia 1 3 limitations of use 1 4 the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias monotherapy ezetimibe tablets administered alone are indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol total c low density lipoprotein cholesterol ldl c apolipoprotein b apo b and non high density lipoprotein cholesterol non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with hmg coa reductase inhibitors statins ezetimibe tablets administered in combination with a 3 hydroxy 3 methylglutaryl coenzyme a hmg coa reductase inhibitor statin is indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with fenofibrate ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia the combination of ezetimibe tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total c and ldl c levels in patients with hofh as an adjunct to other lipid lowering treatments e g ldl apheresis or if such treatments are unavailable ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias" ?g. }

• association label "therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate ezetimibe tablets are an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total c ldl c apo b and non hdl c in patients with primary hyperlipidemia alone or in combination with an hmg coa reductase inhibitor statin 1 1 reduce elevated total c ldl c apo b and non hdl c in patients with mixed hyperlipidemia in combination with fenofibrate 1 1 reduce elevated total c and ldl c in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin 1 2 reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia 1 3 limitations of use 1 4 the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias monotherapy ezetimibe tablets administered alone are indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol total c low density lipoprotein cholesterol ldl c apolipoprotein b apo b and non high density lipoprotein cholesterol non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with hmg coa reductase inhibitors statins ezetimibe tablets administered in combination with a 3 hydroxy 3 methylglutaryl coenzyme a hmg coa reductase inhibitor statin is indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with fenofibrate ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia the combination of ezetimibe tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total c and ldl c levels in patients with hofh as an adjunct to other lipid lowering treatments e g ldl apheresis or if such treatments are unavailable ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias" assertion.